Dapagliflozin effectively improves vascular endothelial functions in Diabetics complicated by CAD
A new study found that Dapagliflozin was found to be safe and efficacious in improving the vascular endothelial functions of patients with diabetes mellitus complicated by coronary artery disease.
Type 2 diabetes mellitus is a major risk factor for cardiovascular disease. Many antidiabetic drugs have been developed which showed good cardiovascular protection. In recent times Dapagliflozin has gained quite a lot of attention because of its cardioprotective effects. Hence, researchers conducted a study to investigate the efficacy of dapagliflozin for diabetes mellitus complicated by coronary artery diseases and its impact on vascular endothelial function in August 2020 and August 2021.
80 patients with coronary heart disease complicated by type 2 diabetes mellitus were recruited and randomly assigned to receive either dapagliflozin at 5 mg daily plus original oral hypoglycemic agents of dapagliflozin group or original oral hypoglycemic agents alone as the control group. Blood pressure, blood glucose, cholesterol levels, vascular endothelial function, cardiovascular events, and drug-related adverse events were the outcomes of measurement.
Results
- The two groups had similar outcome indices upon admission (P > 0.05).
- After 20 weeks of medication, the two groups of patients showed similar blood pressure, hemoglobin A1c (HbA1c), and low-density lipoprotein (LDL-C) levels versus those before treatment (P > 0.05), and no significant differences were found in intergroup comparison neither (P > 0.05).
- When compared with the sole use of conventional hypoglycemic agents, Dapagliflozin plus conventional hypoglycemic agents resulted in a significantly higher reactive hyperemia index (RHI) value, fewer cases with abnormal vascular endothelial function, and fewer major cardiovascular events during treatment (P < 0.05).
- There was no significant difference in drug-related adverse events between the two groups (P > 0.05).
Thus, the researchers concluded that Dapagliflozin improved the vascular endothelial functions of patients with diabetes mellitus complicated by coronary artery disease. It also had a high safety profile and favorable efficacy.
For further reading: 10.1155/2022/4829750
Ma F, Zhang J, Wang H, Wu Y, Wu Y. Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function. Dis Markers. 2022;2022:4829750. Published 2022 Sep 9.
